吉非替尼一线治疗老年晚期肺腺癌临床观察

摘要

ObjectiveTo evaluate the efficacy and adverse effects of Gefitinib as the first line treatment in elderlyrnpatients with lung adenocarcinoma. Methods23 elderly patients of previously untreated advanced lung adenocarcinoma,rnwho were non-smokers and unsuitable for chemotherapy, received Gefitinib treatment until disease progression or intolerable toxicities occurred. The curative effect, performance status of improvement and adverse effects were observed.Results All of the patients were evaluable. Partial response rate and stable disease rate of Gefifinib were 39. 1% and 47. 8% respectively; 65. 2% of patients had performance status improved after treatment.Conclusion Gefitinib has curative effect and is well tolerated in the treatment of elderly patients with previously untreated advanced lung adenocarcinoma.%目的 观察选择吉非替尼一线治疗老年晚期肺腺癌临床疗效及不良反应.方法 23例初治晚期肺腺癌、不吸烟、不适于全身化疗的老年患者接受吉非替尼治疗至疾病进展或不良反应不可耐受,观察近期疗效、体力状态改善情况及不良反应.结果 23例患者均可进行疗效评估,部分缓解率39.1%,疾病稳定率47.8%;治疗后65.2%的患者体力状态有所改善.主要不良反应为Ⅰ/Ⅱ度皮疹、乏力、腹泻.结论 吉非替尼一线治疗老年晚期肺腺癌疗效确切,耐受性良好.